Following are the Top 5 companies based on their one-day percentage change within the 'Freight Market 3PL' theme.

Regeneron Pharmaceuticals, Inc. (REGN)

---

REGN is trading UP for the last 2 days, and it at trading at $979.58 with volume of 324,428 and a one day change of $9.67 (1.00%). Regeneron Pharmaceuticals, Inc. has a 52-week low of 684.81 and a 52-week high of $998.32. The business's 50-day moving average price is $940.81 and its 200 day moving average price is $919.28. The firm has a market cap of $105 million, a P/E ratio of 28.73, and a beta of 0.17.

Top news headlines for REGN

LOS ANGELES, CA / ACCESSWIRE / May 31, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

NEW YORK, NY / ACCESSWIRE / May 31, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN). Investors who purchased Regeneron securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/REGN.

Recommendation for adults with uncontrolled COPD with raised blood eosinophils based on data from two landmark Phase 3 trials demonstrating Dupixent significantly reduced exacerbations and improved lung function

Dupixent recommended for EU approval by the CHMP to treat patients with COPD Recommendation for adults with uncontrolled COPD with raised blood eosinophils based on data from two landmark Phase 3 trials demonstrating Dupixent significantly reduced exacerbations and improved lung function If approved, Dupixent would be the first-ever targeted therapy for COPD in the EU and the first new treatment approach for this disease in more than a decade Paris and Tarrytown, N.Y. May 31, 2024.

TARRYTOWN, N.Y. and PARIS, May 31, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced the U.S. Food and Drug Administration (FDA) has extended by three months the target action date of its priority review of the supplemental Biologics License Application (sBLA) for Dupixent® (dupilumab) as an add-on maintenance treatment in certain adult patients with uncontrolled chronic obstructive pulmonary disease (COPD). The revised target action date is September 27, 2024. The FDA did not raise any concerns regarding the approvability of Dupixent for this indication.

For more information on REGN:

Historical Price Targets

Hiistorical Analyst Recommendations

Earning Price Impact Analysis

Seasonality Analysis

BTC iShares Global Timber & Forestry ETF (WOOD)

---

WOOD is trading UP for the last 1 days, and it at trading at $83.06 with volume of 15,302 and a one day change of $0.25 (0.30%). BTC iShares Global Timber & Forestry ETF has a 52-week low of 69.05 and a 52-week high of $85.29. The business's 50-day moving average price is $81.85 and its 200 day moving average price is $79.66. The firm has a market cap of $0 million, a P/E ratio of 0.00, and a beta of 1.01.

For more information on WOOD:

Historical Price Targets

Hiistorical Analyst Recommendations

Earning Price Impact Analysis

Seasonality Analysis

This article was generated by KlickAnalytics data insight content engine.